subject: Polands Reimbursement Act Will Affect Pharma Market Profits [print this page] The act introduced risk sharing instruments, fixed prices, limit groups and common funding limits to the marketplace. Negotiations with the Ministry of Health reduced prices and lists of refunded drugs have undergone vast changes in recent months. Companies are searching for ways to adapt and excel during these changing times, and PMR has released a new document that addresses precisely those concerns. Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 provides traditional market coverage through the lens of the changes being implemented, revealing their predicted effects for the months and years ahead.
The reimbursement act that entered into force in January 2012 is going to revolutionise the Polish pharmaceutical market. It is going to impact the production of both generic and innovative drugs. The key changes are concerned with fixing the reimbursement expense ceiling at 17% of the whole budget of the National Health Fund, introducing risk-sharing instruments, introducing fixed prices and price margins for refunded drugs, and determining limit groups under a common funding limit.
In order to locate and capitalize on new opportunities, you need direct access to the latest news, sharpest analysis, most reliable statistics and knowledgeable trends forecasting available. Read Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 today, and refer to this new report from PMR on a regular basis as you monitor market expansion and contemplate new business strategies.
This market study examines the generic and innovative drugs industry and delivers data on the share value and volume of these products in terms of overall pharmaceuticals. It lists average prices in Poland and compares them to those of other countries, and supplies data on changes in prices of selected drugs produced by top manufacturers as a result of the legislation.
Issues surrounding government agencies, processes and results are defined and explained in detail, from the reimbursement decision-making process to the payment structure as viewed by both the state and the consumer. In addition to a summary of essential changes produced by the reimbursement act, the effects of fixed reimbursements, limit groups, changes to refunded drugs lists and risk-sharing instruments on the market and its participants are analysed.
The report profiles the top producers of generic and innovative drugs in Poland and provides an assessment of the ways in which the new policies have impacted the prices of their products, market demand and other operations. It offers suggested action plans that might alleviate negative impact on companies adapting to new industry structures now and for the future, along with forecasts for market direction until 2014.
